Kyverna Therapeutics, Inc.

Healthcare

NASDAQ:KYTX · NASDAQ Global Select

Market Cap $352.74M Beta 1.96 P/E (TTM) -3.1

$8.06 +2.35%

+$0.19 today

52W Low $2.52High $13.67

Vol 0.65M · Avg 0.93M

EPS (TTM)-$2.59

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+150.16%

Period High

$11.25

Period Low

$2.55

Latest

$8.06

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Capricor Therapeutics, Inc.

NASDAQ:CAPR

$1.18B

Cabaletta Bio, Inc.

NASDAQ:CABA

$490.79M

Allogene Therapeutics, Inc.

NASDAQ:ALLO

$463.35M

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

$444.15M

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

$359.32M

Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

$343.14M

Silence Therapeutics plc

NASDAQ:SLN

$316.00M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

$315.01M

Editas Medicine, Inc.

NASDAQ:EDIT

$244.75M

Mereo BioPharma Group plc

MREO

$48.68M

What is the latest KYTX filing?

The latest filing shown is 8-K dated Jun 2, 2026.

How many recent filings does KYTX have?

Intrinsic Alpha currently shows 20 recent filings for KYTX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.